SCHEMBL29523653

SCHEMBL29523653

CC(C)(C)OC(=O)NCc1cc2c(s1)CCNC2=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 2/20 0.39
PIM2 Q9P1W9 2/20 0.39
CDC7 O00311 1/20 0.38
DBF4 Q9UBU7 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.36
KDM4A O75164 1/20 0.36
BRD4 O60885 1/20 0.35
CREBBP Q92793 1/20 0.35
DDB1 Q16531 1/20 0.34
CRBN Q96SW2 1/20 0.34
PARP1 P09874 1/20 0.34
PARP2 Q9UGN5 1/20 0.34
LMNA P02545 2/20 0.34
KDM4E B2RXH2 1/20 0.34
PRMT5 O14744 1/20 0.34
WDR77 Q9BQA1 1/20 0.34
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA9 Q16790 2/20 0.33
CACNA1H O95180 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29524144 0.87 KDM4E (0.38) L3MBTL1KDM4ABRD4CREBBPLMNA
SCHEMBL30571590 0.81 L3MBTL1 (0.36) PIM1PIM2L3MBTL1KDM4ABRD4
SCHEMBL29523623 0.76 CA1 (0.36) L3MBTL1KDM4ALMNAKDM4ECA1
SCHEMBL30571964 0.74 KDM4E (0.39) L3MBTL1KDM4ALMNAKDM4EPRMT5
SCHEMBL29523059 0.74 HTT (0.38) L3MBTL1KDM4ALMNAKDM4ECA1
SCHEMBL29761421 0.70 CRBN (0.51) DDB1CRBN
SCHEMBL27153587 0.68 ALDH1A1 (0.45) PIM1CDC7DBF4L3MBTL1PARP1
SCHEMBL2048612 0.67 GPR119 (0.46) L3MBTL1KDM4ABRD4CREBBPPARP1
SCHEMBL30571536 0.67 CA1 (0.37) L3MBTL1KDM4ALMNAKDM4ECA1
SCHEMBL31351705 0.65 PARP11 (0.49) BRD4CREBBPCA1CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4216946-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Achillion Pharmaceuticals, Inc. (US) 2023-08-02 EP disclosed
WO-2022066774-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2022-03-31 WO disclosed